Currently, three EGFR tyrosine kinase inhibitors (EGFR-TKIs) including the first-generation, reversible TKI erlotinib and gefitinib as well as the second-generation irreversible TKI afatinib are approved for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations [5]. Here, EGFR is linked to non-small cell lung carcinoma.